We determined HIV infections in the Rakai cohort before (82/9434) and after (131/13082) the availability of antiretroviral therapy (ART). The proportions of total HIV infections pre-ART and post-ART were 18.3% and 13.7%, respectively, among identifiable HIV-discordant couples, 23.2% and 26.0%, respectively, in concordant HIVnegative couples, 29.3% and 17.6% in married persons with unknown partner status, and 29.3% and 42.7% in the unmarried. Voluntary counseling and testing targeting discordant couples is unlikely to have a substantial impact in this setting.
We examine for the first time age-mixing in sexual relationships in a population with very high HIV incidence and prevalence in rural South Africa. The highest levels of age assortativity (the pairing of like with like) were casual partnerships reported by men, the lowest levels were spousal relationships reported by women. Given the age-sex distribution of HIV prevalence in this population, interventions to decrease age-gaps in spousal relationships may be effective in reducing HIV incidence.
Age-mixing in sexual relationships may influence the spread of infectious diseases [1] [2] [3] [4] . Information on agemixing is crucial for investigating HIV epidemic dynamics [5] [6] [7] but rarely available for sub-Saharan Africa (SSA), with few notable exceptions [8] . In South Africa, age-gaps in sexual relationships have been reported as the proportion of partners in 5-year age categories around the age of the reporting partner [9, 10] . However, no studies in South Africa have described continuously measured age-gaps, presented age-gap information by relationship type, or assessed the degree of age assortativity (the pairing of 'like with like' with respect to age) [11] .
We used data from one of the largest HIV surveillances in SSA [12] [13] [14] in a community in rural South Africa with both high adult HIV prevalence (21%) [15] and incidence (3 per 100 person-years) [13] . Women and men aged 15 years or older were eligible to participate [16] .
Participants were asked about their most recent sexual partners (up to three) and, for each partner, about the 'relationship to that partner' and whether the partner was 'older, younger or about the same age'. A follow-up question ascertained the age difference in years, if same age was not reported [17] . Although it is possible that age self-reporting is biased, our data were collected within an established longitudinal demographic surveillance system in which age is ascertained at repeat visits, potentially reducing misreporting [18] .
We calculated the age-gap in each relationship by subtracting the woman's age from the man's age. We constructed mixing matrices stratified by sex of respondent and relationship type with ages divided into 5-year categories. We quantified age assortativity by sex and relationship type by computing median age-gaps and Gupta et al.'s Q [19] on the mixing matrices:
in which w i are the eigenvalues of the mixing matrix and N is the number of age categories. Q quantifies the proportion of partnerships that occur within the same age group [20] . Q can be used to compare different samples of relationships, as long as the age categories of the mixing matrices are the same. Q is 1 when all relationships occur between people in the same age group, 0 when age group mixing is proportional and À1/(N-1) when all relationships occur between people in different age groups. Although Q does not have a natural interpretation outside these three extreme values [20] , it does allow ranking of relationships on a continuum from maximum disassortativity to maximum assortativity. To estimate the variance of Q, we carried out 10 000 bootstrap replications with replacement [21] . We fit multivariable models to identify the shape of the association between age-gap and independent variables (age, sex and relationship type), using likelihood-ratio tests to compare nested models.
One thousand three hundred and forty-nine men and 2768 women provided information on a total of 4437 partners. After comparing every combination of main-effect models and models with every combination of twoway and three-way interactions, the best fitting model included all two-way interaction terms between age (modelled quadratically), sex and relationship type and their main effects (see Fig. 1 for the age-gaps predicted from the model). Among male respondents, age-gaps increased for all four relationships types through age 50 and decreased after age 50 (in casual relationships), after the mid-60s (spousal relationships) and after the mid-70s (former spousal and casual relationships). Age-gaps between women and their causal partners increased until the early 30s, after which they decreased rapidly. Age-gaps between women and their former spouses or partners held fairly constant until age 35 and then decreased. The age-gap between female respondents and their current partners reached a maximum of about 4.5 years in women above 40 years of age.
Past studies have linked age-gaps to increased risk of HIV infection in SSA [1, 7, [22] [23] [24] [25] . Our study provides a finely detailed description of the age-mixing patterns in a rural population in SSA, in which HIV prevalence peaks 5 years earlier in women than in men [12, 26] . When a young woman enters a sexual relationship with an older man, as frequently occurs, we would thus expect that she is at a higher risk of contracting HIV than if she entered a relationship with a man of her own age. Age-gaps are often hypothesized to be largest in casual relationships, coinciding with compensation for the younger female partner, for example gifts from a 'sugar daddy' (a man at least 10 years older than his casual partner) [27] . We find that regardless of the sex or age of the respondent, spousal relationships have substantially larger age-gaps than casual relationships and 'sugar daddy' relationships are quite rare in this population. Age-gaps in spousal relationships may be large because men may need to save money over a long time to accumulate enough wealth to pay lobola, the traditional bride price in this community [2, 28] . By the time a man can afford lobola, he may have engaged in several relationships with casual partners, increasing his and his future wife's risk of HIV infection.
Future studies should estimate the effect of age-gaps on the hazard of HIV acquisition and try to assess whether any such effects are due to the HIV age distributions in men and women or due to differences in sexual risktaking by age-gaps [22] . If age-gaps in sexual relationships are indeed important factors in HIV acquisition,
interventions that reduce the gaps should be developed [29, 30] , for example informing women that older men are more likely to be HIV-infected than younger men or providing loans for lobola for young men. 
Introduction
Understanding the transmission dynamics of generalized HIV epidemics is a key to prevention strategies. One model estimated that the majority of infections occurred within long-term stable HIV-serodiscordant couples, suggesting that couples voluntary counseling and testing (CVCT) could prevent transmission, mitigating the epidemic [1, 2] . An alternative approach estimated that upwards of two-thirds of infections occurred via multiple partnerships, predominantly outside of stable relationships, and thus would not be amenable to a CVCT intervention [3] . We examined this issue using data on incident infections from Rakai, Uganda before and after the availability of antiretroviral therapy (ART).
Methods
The Rakai Community Cohort Study conducts census and serosurveys among consenting residents aged 15-49 years in 50 rural communities of rural Rakai District [4] . For respondents who are married (including stable consensual relationships), we request information on their spouse or partner which allows linkages of couple data to partners residing in the study areas, and approximately 68% of married or consensual individuals (hereafter referred to as 'married') have an identifiable linked partner.
We assessed incident HIV infections among initially HIVnegative cohort participants observed during two intersurvey intervals; one intersurvey interval prior to the availability of ART and one after ART services were available. The pre-ART intersurvey interval used data collected from two surveys; the first conducted from We divided the population into HIV-negative participants who were not currently married at the beginning of an intersurvey interval (i.e. never married, or previously married but currently separated, divorced or widowed) and persons who were currently married at the beginning of an intersurvey interval. The currently married were further disaggregated into couples in which both partners were concordantly HIV-negative at the start of the interval, couples who were HIV-discordant, and married persons whose partner's HIV status was unknown (e.g. the partner was absent or refused participation).
We then tabulated the proportion of all new HIV infections observed during the intersurvey intervals by the marital and HIV status of the participants at the initial survey. Our main focus was on the proportion of total incident infections that occurred among couples whose primary relationship was HIV-discordant. In Rakai, most people eventually marry, and divorce is relatively infrequent [5] . More than 90% of participants agree to HIV testing [4] .
Results
The distribution of the populations at the beginning of the intersurvey intervals and the number of incident HIV infections during follow-up are shown in Table 1 . 
Discussion
Our data indicate that only a minority of total HIV infections occur to a person in an identifiable stable HIVdiscordant couple relationship in this generalized HIV epidemic setting. In much of Southern Africa where age of first marriage is delayed, an even smaller proportion of people are in stable partnerships than in Eastern Africa [6, 7] . Moreover, viral sequencing showed that 29% of new infections in the previously negative partner in a discordant relationship came from a partner outside the primary relationship [8] . Thus, in addition to the question of the efficacy of a CVCT intervention with couples, universal VCT targeted on HIV-discordant couples is unlikely to have a major impact on the epidemic [1, 2] . Although it might be argued that our observed infection rates were lowered because of counseling and disclosure among the discordant couples, disclosure and acceptance of couples counseling has been quite low in this cohort, despite efforts to promote CVCT. Part of the explanation for this minority contribution of new infections among identifiable HIV-discordant couples is that infectivity is quite low during the chronic phase of infection [9, 10] .
The data post-ART reflect an even lower proportion of transmissions from within identifiable discordant couples, perhaps suggesting some collateral benefit of ART in reducing infectivity [11] . Thus, although there is definite merit to counseling and testing, including counseling of couples, it is likely to have limited impact, particularly if the focus remains on those testing positive and on discordant couples. Rather, prevention efforts need also to embrace specific interventions, such as male circumcision, condoms and behavior change to limit outside partners, aimed at the broader population in which most infections are occurring.
Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort
Rodolphe Thié baut a , Sophie Matheron b , Audrey Taieb a , Francoise Brun-Vezinet b , Geneviève Chêne a , Brigitte Autran c , for the immunology group of the ANRS CO5 HIV-2 cohort
Among 342 HIV-2-infected patients of the ANRS CO5 HIV-2 cohort, the prevalence of long-term nonprogressors (LTNPs) (i.e. asymptomatic for at least 8 years while maintaining CD4 cell count at least 500 cells/ml) and of HIV controllers (i.e. controlling HIV replication in the absence of antiretroviral treatment for at least 10 years) was 6.1% (95% confidence interval 3.9-9.1) and 9.1% (6.3-12.7), respectively. Most LTNPs (81%) were HIV controllers, whereas only 55% of HIV controllers were LTNPs.
Studies of nonpathogenic simian immunodeficiency virus (SIV)/HIV infections are important to understand the mechanisms of protection against the disease. Models of highly informative subgroups include natural hosts infections [1] , long-term nonprogressors (LTNPs) who remain asymptomatic for many years and maintain high CD4 cell counts, or HIV controllers who spontaneously control HIV replication, in the absence of antiretroviral treatment. Comparisons of viruses and hosts characteristics between these subgroups, those who progressed and uninfected individuals, help in finding correlates of protection against infection and/or progression [2] .
Recently, Grabar et al. [3] showed that both conditions are very rare in the very large ANRS CO4 French HIV Database of HIV-1-infected patients: LTNPs being twice as frequent as HIV controllers (0.43 vs. 0.22% among 46880 patients). Furthermore, there was a partial overlap between the two subgroups. On the one hand, only 42% of HIV controllers were LTNPs; in this situation, one of the main hypothetical mechanisms is that immune activation deteriorates the immune system, even though viral replication is controlled. On the other hand, 79% of LTNPs were not HIV controllers, a situation comparable to that of African green monkeys and sooty mangabeys that are natural host of SIVand in which the consequences of ongoing viral replication are controlled by the regulation of immune activation [4] .
HIV-2 infection is another example of a reduced pathogenic infection with a lower risk of disease progression and transmissibility than HIV-1, which has already been related to differences in virus and host factors [5] . So far, the variability of disease progression in HIV-2infected individuals has been poorly characterized [6] . This can be achieved through the estimation of the frequency of LTNPs and HIV controllers. The ANRS CO5 cohort is a cohort of HIV-2 patients that has included a total of 749 patients as of 2009 [7] . Briefly, it is an ongoing national prospective study initiated in 1994 in 111 clinical centers in France. Inclusion criteria to the cohort are HIV-2 infection only, age 18 years or greater, residence in France planned for at least 1 year and informed consent available. According to the same criteria used in HIV-1-infected patients and the same selection process [3] , the frequency of LTNPs (asymptomatic HIV infection !8 years, nadir CD4 cell count !500 cells/ml without antiretroviral therapy) and HIV controllers (asymptomatic HIV infection !10 years, 90% of plasma HIV-2 RNA 500 copies/ml) were 6.1% [n ¼ 21/342, 95% confidence interval (CI) ¼ 3.9-9.1] and 9.1% (n ¼ 31/342, 95% CI 6.3-12.7), respectively (Figure in Supplemental Digital Content, http:// links.lww.com/QAD/A118). Frequency of elite LTNPs (nadir CD4 cell count >600/ml, and nondeclining CD4 cell count slope) and elite HIV-2 controllers (last plasma HIV-2 RNA below the detection limit of 100 copies/ml) were 1.5% (n ¼ 5, 95% CI 0.54-3.2) and 8.8% (n ¼ 30, 95% CI 6.1-12.1), respectively. Hence, all but one HIV controllers were elite controllers (30/31). Looking at the overlap between these two groups, 55% (n ¼ 17/31, 95% CI 37.3-71.5) of HIV controllers were LTNPs and 19% (n ¼ 4/21, 95% CI 6.4-39.8) of LTNPs were not HIV controllers. In comparison with data reported on HIV-1 infection, it is noteworthy that LTNPs and HIV controllers were 10-40-fold more frequent among HIV-2-infected patients (all P < 0.0001), HIV controllers being more frequent than LTNPs. Furthermore, the proportion of HIV controllers among LTNPs is four-fold more important than for HIV-1 (Fig. 1) .
The estimates of the frequency of LTNPs and HIV controllers were provided for the purpose of comparison with the results in HIV-1-infected patients and the calculation followed the same rules, but they should be interpreted with caution in the context of HIV-2 infection for two reasons. First, the requirement of duration of the follow-up available greater than 8 years may have led to a potential underestimation of LTNPs and HIV controllers. However, we believe that, in the context of universal access to care, this was also the case for HIV-1 estimates and this should not modify the overlap between the groups. Second, both studies are based on clinical cohorts that cannot include patients who are not yet diagnosed, especially because they remain asymptomatic, in a context of universal access to care [8] . We, therefore, believe our study yielded an underestimation of the frequency of LTNPs and HIV controllers.
This simple description of extreme groups in the HIV-2 cohort illustrates the differences in HIV replication and disease progression between these two retroviral infections and provides some insight into potential mechanisms of progression and nonprogression in this population of infected patients. Low HIV-2 replication appears to be the main characteristic of LTNPs, although some of the HIV-2 controllers experienced disease progression as in HIV-1 infection. Lymphocyte activation and/or other hypothetical causes of immune deterioration may also play an important role in HIV-2 disease that remain to be explored more deeply in relation to this low replicative capacity of HIV-2. We aimed to determine the contribution of high-density lipoprotein cholesterol (HDL-c) to cardiovascular disease (CVD) risk in a cohort of HIV-infected patients. The contribution of CVD risk factors to the predicted CVD risk was assessed. We estimated the degree of reclassification of CVD risk if HDL-c concentration was increased in all patients by 20 and 40%, respectively. After age, HDL-c contributed most to the overall cardiovascular risk. Increasing HDL-c by 20% and 40% reclassified six and 12 patients to lower CVD risk groups, respectively. In this cohort, HDL-c contributed more to cardiovascular risk than smoking, total cholesterol, systolic blood pressure (SBP) and sex.
HIV-1 infection is associated with decreased high-density lipoprotein cholesterol (HDL-c) concentration and increased risk of cardiovascular disease (CVD) [1, 2] . Traditional CVD risk calculators stratify risk around specific low-density lipoprotein cholesterol (LDL-c) targets as the primary focus for intervention. However, as there is a high prevalence of low HDL-c in HIVinfected patients [present in more than 60% of patients prior to antiretroviral therapy (ART)] [3] , we aimed to determine the relevant contribution of HDL-c to CVD risk in a contemporary cohort of HIV-infected patients and postulated that HDL-c is an important contributor to cardiovascular risk in this patient population.
We performed a cross-sectional study of HIV-infected patients attending the Infectious Diseases Outpatient Clinic at the Mater Misericordiae University Hospital from February 2008 to February 2010. Patients provided their written, informed consent and ethical approval was obtained. Information on demographics, HIV infection and treatment history, together with clinical assessments and laboratory investigations were gathered.
Ten-year risk of CVD was estimated using the Framingham equation [low (<10%), moderate (10-20%) and high (>20%) risk] [4] . The contribution of each known CVD risk factor [age, sex, current smoking, total and HDL-c, systolic blood pressure (SBP) and diabetes mellitus] to the predicted risk at a cohort level was assessed by fitting a multiple linear regression model with 10-year predicted risk as the outcome and each of the seven CVD risk factors as covariates. We excluded each factor in turn to calculate the proportion of the variation in the predicted risk that was explained by each factor alone. We also estimated the degree of reclassification of CVD risk and number of CVD events averted if HDL-c concentration was increased in all patients in the cohort by 20 and 40%, respectively.
Of 134 patients recruited, 127 patients had sufficient CVD risk information for inclusion in the analyses; among this subgroup, the median age was 37 years (range 21-62), 65% of patients were male and 58% Caucasian. Acquisition risk groups were all represented: heterosexual acquisition (55%); men who have sex with men (21%); and injection drug users (21%). The median CD4 þ T-cell count was 378 cells/ml (interquartile range 263). Two thirds (n ¼ 83, 65%) of patients were on ART, of whom 86% were virologically suppressed (HIV-RNA < 50 copies/ml). Of the 83 patients, 95% were on ART regimens including nucleoside or nucleotide reverse transcriptase inhibitors, 43% were on nonnucleoside reverse transcriptase inhibitors and 57% were on ritonavir-boosted protease inhibitors. Thirty-eight percent of patients were smokers, 20% had a family history of cardiovascular disease, 11% were hypertensive and only 1% had a diagnosis of diabetes mellitus. One hundred and ten patients had low CVD risk, 12 had moderate risk and five were classified as high risk. As per National Cholesterol Education Programme (NCEP) guidelines, 3% had elevated total cholesterol, 53% had low HDL-c and 5% had elevated LDL-c [5] .
Among the CVD risk factors considered, HDL-c ranked second, after age, as the factor that contributed most to overall CVD risk ( Fig. 1) , above both smoking and totalcholesterol. Increasing HDL-c by 20% and 40% led to reclassification of six and 12 patients to a lower CVD risk group, respectively. Increasing HDL-c concentration by 20% would result in the reclassification of one patient from high to moderate CVD risk and five patients from moderate to low risk. This would potentially avert 1.26 CVD events over 10 years. Increasing HDL-c concentration by 40% would result in the reclassification of two patients from high to moderate risk and 10 patients from moderate to low risk, potentially averting 2.14 CVD events over 10 years.
Our data highlight the important contribution of low HDL-c to CVD risk in HIV-infected patients, with HDL-c contributing more to 10-year cardiovascular risk than smoking, total cholesterol, SBP or sex. Although our study is limited by a relatively small sample size, our cohort is sufficiently representative of a contemporary HIV-infected population. While in-vitro studies suggest a role for viral proteins in inhibiting cholesterol efflux from cells, thereby contributing to low HDL-c [6, 7] , little is known of the underlying mechanisms for persistent low HDL-c in patients on ART. In addition, existing therapeutic options to raise HDL-c are limited. Both 3-hydroxy 3-methylglutaryl CoA reductase inhibitors and niacin have little appreciable effect on HDL-c [8, 9] , although newer agents are under development [10] .
Results from this study demonstrate the importance of further research into the causes of low HDL-c in HIVinfected patients and the effect of ART on low HDL-c. Furthermore, validation of these results in larger epidemiological studies, such as the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study, is necessary to determine the impact of low HDL-c on CVD events in HIV-infected patients.
In summary, in a cohort of HIV-infected patients, HDL-c contributed more to CVD risk than smoking, total cholesterol, SBP and sex. Further research is warranted, in order to explain why HDL-c is low in HIV-infected patients and identify potential therapeutic targets. 
